We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+32.57%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$628M
AUM Growth
+$187M
Cap. Flow
+$205M
Cap. Flow %
32.59%
Top 10 Hldgs %
40.48%
Holding
169
New
52
Increased
19
Reduced
22
Closed
47

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$59.7M
2
NUVL
Nuvalent
NUVL
+$10.3M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$10.1M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.47M
5
IRON icon
Disc Medicine
IRON
+$8.52M

Top Sells

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$14.4M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.5M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$7.11M
4
BLU
BELLUS Health Inc.
BLU
+$6.37M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.19M

Sector Composition

Rank Sector Weight
1 Healthcare 44.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOD icon
101
Kodiak Sciences
KOD
$2.5B
$431K 0.07%
62,527
-100,000
-62% -$612K
BCLI
102
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$391K 0.06%
12,662
– –
MRSN
103
CALL
DELISTED
Mersana Therapeutics
MRSN
$364K 0.06%
+4,424
New +$647K
ANEB
104
DELISTED
Anebulo Pharmaceuticals
ANEB
$341K 0.05%
156,203
– –
ELDN icon
105
Eledon Pharmaceuticals
ELDN
$255M
$304K 0.05%
221,830
– –
MREO
106
Mereo BioPharma
MREO
$48.9M
$300K 0.05%
+891,676
New +$1.03M
CMMB
107
Chemomab Therapeutics
CMMB
$10.7M
$280K 0.04%
53,348
-5,829
-10% -$36.8K
PNT
108
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$261K 0.04%
28,784
-110,781
-79% -$977K
CNTB
109
Connect Biopharma Holdings
CNTB
$129M
$244K 0.04%
219,501
– –
VRNA
110
DELISTED
Verona Pharma
VRNA
$219K 0.03%
313,677
+85,000
+37% +$1.81M
ASND icon
111
Ascendis Pharma A/S
ASND
$16.5B
$187K 0.03%
+2,090
New +$182K
NUVL
112
CALL
DELISTED
Nuvalent
NUVL
$186K 0.03%
+4,400
New +$166K
MRSN
113
DELISTED
Mersana Therapeutics
MRSN
$165K 0.03%
+2,000
New +$293K
RLMD icon
114
Relmada Therapeutics
RLMD
$540M
$161K 0.03%
65,491
– –
SYBX
115
DELISTED
Synlogic
SYBX
$132K 0.02%
20,450
– –
KDNY
116
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$130K 0.02%
283,464
– –
TECX
117
Tectonic Therapeutic
TECX
$536M
$127K 0.02%
+11,179
New +$126K
FHTX icon
118
Foghorn Therapeutics
FHTX
$278M
$106K 0.02%
+15,000
New +$105K
FNCH
119
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$67.5K 0.01%
7,917
-1
-0% -$10
ASLN
120
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$29.8K ﹤0.01%
20,511
– –
MDGL icon
121
Madrigal Pharmaceuticals
MDGL
$12.6B
$17.3K ﹤0.01%
75
– –
PHXM
122
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.26K ﹤0.01%
302
-24,541
-99% -$216K
ACAD icon
123
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-60,000
Closed -$1.13M
ACHV icon
124
Achieve Life Sciences
ACHV
$633M
– –
-174,714
Closed -$990K
ACRS icon
125
CALL
Aclaris Therapeutics
ACRS
$715M
– –
-589,300
Closed -$4.77M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Ikarian Capital held 169 positions worth $628M, up 42% from $441M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ikarian Capital deployed $205M of net new capital in Q2 2023, opening 52 new positions and adding to 19 existing holdings. Its largest new stake was ACELYRIN: 2,918,426 shares worth $61M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 53% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $7.11M trimmed.

  • Ikarian Capital's largest Q2 2023 buy was ACELYRIN: 2,918,426 shares worth $61M.
  • Ikarian Capital added most to Apellis Pharmaceuticals in Q2 2023, an estimated $2.92M increase.
  • Ikarian Capital's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $7.11M.
  • Ikarian Capital fully exited Immunovant in Q2 2023, selling an estimated $14.4M.
  • Ikarian Capital's ten largest holdings make up 40% of its $628M portfolio in Q2 2023.
  • Ikarian Capital opened 52 new positions and closed 47 in Q2 2023.
  • Ikarian Capital's portfolio value rose 42% quarter-over-quarter to $628M.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.